Interestingly, we demonstrated that GSDMB is a novel therapeutic cancer target, since its multiple pro-cancer functions in HER2+/GSDMB + breast cancer cells were reduced in vitro and in vivo by the intracellular delivery of a GSDMB antibody through biocompatible nanocapsules (Molina-Crespo et al., 2019). The gene discussed is ERBB2; the disease is cancer.